Clinical Trials

Neuroendocrinologic Tumors

Recruitment stopped
Ongoing Recruitment

Clarinet forte (8-79-52030-326)

(second-line)
Title:Efficacy and Safety of Lanreotide Autogel® 120 mg Administered Every 14 Days in Well Differentiated, Metastatic or Locally Advanced, Unresectable Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg Administered Every 28 Days
Indication:Apudoma Carcinoid Tumor Neoplasms Neuroendocrine Tumors Pancreatic Neoplasms
Type of study:Phase II
Contact: Julia Weck (Study Nurse)
[julia.weck@med.uni-heidelberg.de]
Investigator: Dr. med. Leonidas Apostolidis (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02651987
EudraCT: 2014-005607-24 (siehe EU klinisches Studienregister)

EVINEC (NEC G3 / AIO-NET-0112)

(second-line)
Title:Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
Indication:Poorly differentiated neuroendocrine carcinoma, neuroendocrine carcinoma G3 (NEC G3 according to WHO 2010) with primary tumor outside lung; Well to moderately differentiated neuroendocrine carcinoma (NET G1 / G2) that switched to G3 (confirmed by histology); Neuroendocrine tumor G3 (NET G3)
Type of study:Phase II
Contact: Julia Weck (Study Nurse)
[julia.weck@med.uni-heidelberg.de]
Investigator: Dr. med. Leonidas Apostolidis (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02113800
EudraCT: 2012-004550-28 (siehe EU klinisches Studienregister)

GPOH-MET-Register (Fortführung von GPOH-Met97)

(pädiatrisch, epidemiologisch)
Title:GPOH-MET-Register, Register zur Erfassung maligner endokriner Tumoren im Kindes- und Jugendalter
Indication:Kinder/Jugendliche mit endokrinen Tumoren: Schilddrüsenkarzinome, Nebennierenrindentumoren, Phäochromozytome/ Paragangliome, Gastroenteropankreatische Neuroendokrine Neoplasien
Type of study:Phase N/A
Contact: Renate Sedlak (Study Nurse)
[renate.sedlak@med.uni-heidelberg.de]
Investigator: Dr. med. Wolfgang Behnisch (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

AveNEC

Title:A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in patients with advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first line chemotherapy (AveNEC)
Indication:Patients with advanced neuroendocrine carcinomas NEC G3 (WHO 2010) (excluding SCLC and Merkel cell carcinomas) who experienced tumor progression within 9 months after prior chemotherapy
Type of study:Phase II
Contact: Julia Weck (Study Nurse)
[julia.weck@med.uni-heidelberg.de]
Investigator: Dr. med. Leonidas Apostolidis (Leiter klinische Prüfung)
Trial Register: No trial registry number given.
EudraCT: 2016-004373-40 (siehe EU klinisches Studienregister)